Ergocalciferol in Chronic Kidney Disease

The Effect of Ergocalciferol Treatment on 25-Hydroxyvitamin D Levels and Plasma Intact PTH in Patients With Chronic Kidney Disease Stage 3 and 4

To examine the effect of ergocalciferol treatment on 25-hydroxyvitamin D and PTH levels in patients with CKD stage 3 and 4

Inclusion Criteria:

• Patient with CKD stage 3 or 4 whose 25-hydroxyvitamin D levels are below 30 ng/ml and plasma intact PTH levels >70 pg/ml.

Exclusion Criteria:

• Patients who are on any form of active vitamin treatment